FDA Brief

Warning letters Food

FDA warning letter to

Phytag Labs

MediumIssued Sep 7, 2021Posted Sep 9, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA and FTC warn Phytag Labs that its GLUCOTYPE2 supplement is an unapproved drug and misbranded due to diabetes treatment claims.

What happened

In August 2021, FDA reviewed Phytag Labs' website and Amazon storefront and found claims that GLUCOTYPE2 controls blood sugar, treats Type 2 diabetes, lowers cholesterol, and reduces nerve pain. FDA determined the product is a new drug without FDA approval and is misbranded because it lacks adequate directions for use. FTC also reviewed the websites and demanded that the company stop making unsubstantiated disease claims.

What FDA found

  1. FDA says the website and Amazon claims make GLUCOTYPE2 a drug intended to treat disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. FDA says GLUCOTYPE2 is a new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.

    section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. FDA says the product is misbranded because it lacks adequate directions for safe lay use of a drug for diseases that require a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 C.F.R. 201.5
  4. FDA says selling the misbranded drug across state lines violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]
  5. FTC says the company advertised that GLUCOTYPE2 prevents, treats, or cures diabetes without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. ยง 41 et seq.

What FDA wants

Notify FDA in writing within 15 working days of the specific steps taken to address the violations, including explanations, prevention steps, and supporting documents; if more time is needed, state the reason and timeline.

Who should pay attention

  • dietary supplement brands that make disease-treatment claims
  • retailers and Amazon sellers listing supplement products
  • marketers of diabetes-related supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk